IL-15 fusion

IL-15 fusion proteins represent a diverse class of engineered immunotherapeutic agents designed to enhance the therapeutic potential of Interleukin-15 (IL-15). Native IL-15 is a potent stimulator of CD8+ effector T cells and natural killer (NK) cells but suffers from a short half-life and a requirement for trans-presentation by the IL-15 receptor alpha (IL-15Rα) subunit. To overcome these limitations, IL-15 fusion proteins typically incorporate the IL-15Rα sushi domain (creating a 'superagonist' complex), an Fc fragment or albumin-binding domain for extended pharmacokinetics, and sometimes a tumor-targeting moiety (such as an antibody or nanobody) to localize activity to the tumor microenvironment. These molecules aim to promote robust anti-tumor immune responses while minimizing the systemic toxicities associated with high-dose cytokine therapy. Multiple candidates, including BJ-001, SON-1210, and KD033, are currently in various stages of clinical and preclinical development for the treatment of advanced solid tumors.

Other names

IL-15 fusion proteinIL15 fusion proteinIL 15 fusion proteinIL-15 immunocytokineIL15 immunocytokineIL 15 immunocytokineIL-15 superagonistIL15 superagonistIL 15 superagonistIL-15Rα/IL-15 fusion